| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1983.1.2.146 |
| P698 | PubMed publication ID | 6689425 |
| P2093 | author name string | S A Rosenberg | |
| P Carde | |||
| F R MacKintosh | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 146-153 | |
| P577 | publication date | 1983-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy | |
| P478 | volume | 1 |
| Q43866927 | A risk factor for relapse in Hodgkin's disease: female gender? |
| Q37348243 | A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. |
| Q33334950 | Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). |
| Q67820006 | An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP |
| Q74682586 | Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study |
| Q73203647 | BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group |
| Q35331114 | Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it? |
| Q37732507 | Chemotherapy of Hodgkin's disease |
| Q35706730 | Clinical aspects of Hodgkin's disease |
| Q39647429 | Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity |
| Q38649105 | Clinical pharmacokinetics-pharmacodynamics of anticancer drugs |
| Q53326637 | Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. |
| Q42840229 | Compliance and cancer chemotherapy |
| Q39834906 | Current management of Hodgkin's disease |
| Q34629955 | Dose intensity in cancer chemotherapy |
| Q72326122 | Dose optimisation and dose intensification in malignant lymphoma |
| Q69747724 | Factors causing dose variability in drug administration |
| Q37163738 | High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia |
| Q44613053 | Hodgkin's disease in adults in Saudi Arabia. Clinical features, prognostic factors and an analysis of therapy. Outcome of combination chemotherapy only, for both localized and advanced disease |
| Q30425816 | Hodgkin's disease: historical perspective and clinical presentation |
| Q35662615 | Hodgkin's lymphoma. II: Treatment and delayed morbidity |
| Q36467596 | Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease |
| Q70496897 | Is anything better than MOPP? |
| Q40625823 | Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. |
| Q35038832 | Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma |
| Q34696326 | New treatments for Hodgkin's disease |
| Q39768346 | Pharmacokinetics of anticancer drugs in children |
| Q62096508 | Prognostic Factors |
| Q36466659 | Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres |
| Q62096688 | Prognostic factors in Hodgkin's disease |
| Q48017001 | Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group |
| Q53540758 | Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. |
| Q35977542 | Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. |
| Q73368641 | Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease |
| Q33862700 | The Role of Adjuvant Radiation Therapy for Stages III and IV Hodgkin's Disease |
| Q36467090 | The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy |
| Q35992880 | The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia |
| Q39696953 | The radiology of lymphoma |
| Q37235019 | Treatment of Hodgkin lymphoma: the past, present, and future. |
| Q39696912 | Treatment of Hodgkin's disease |
| Q77406542 | [The role of radiotherapy in the management of advanced Hodgkin's disease] |
Search more.